Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)

We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Hiromi, Ichihara, Eiki, Kano, Hirohisa, Ninomiya, Kiichiro, Tanimoto, Mitsune, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596283/
https://www.ncbi.nlm.nih.gov/pubmed/28781309
http://dx.doi.org/10.2169/internalmedicine.8344-16
_version_ 1783263501949599744
author Watanabe, Hiromi
Ichihara, Eiki
Kano, Hirohisa
Ninomiya, Kiichiro
Tanimoto, Mitsune
Kiura, Katsuyuki
author_facet Watanabe, Hiromi
Ichihara, Eiki
Kano, Hirohisa
Ninomiya, Kiichiro
Tanimoto, Mitsune
Kiura, Katsuyuki
author_sort Watanabe, Hiromi
collection PubMed
description We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. She was diagnosed with congestive heart failure caused by the osimertinib. In contrast to trastuzumab, a human epidermal growth factor receptor 2 (HER2) monoclonal antibody that often causes cardiac dysfunction, the causal relationship between osimertinib and cardiotoxicity has so far received little attention and thus remains unclear. However, it inhibits HER2 in addition to mutant EGFR, thereby potentially causing cardiotoxicity.
format Online
Article
Text
id pubmed-5596283
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-55962832017-09-14 Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC) Watanabe, Hiromi Ichihara, Eiki Kano, Hirohisa Ninomiya, Kiichiro Tanimoto, Mitsune Kiura, Katsuyuki Intern Med Case Report We herein report a case of congestive heart failure which developed during osimertinib treatment. A 78-year-old woman presented with mild exertional dyspnea three weeks after starting osimertinib for the treatment of epidermal growth factor receptor (EGFR) T790M-positive non-small cell lung cancer. She was diagnosed with congestive heart failure caused by the osimertinib. In contrast to trastuzumab, a human epidermal growth factor receptor 2 (HER2) monoclonal antibody that often causes cardiac dysfunction, the causal relationship between osimertinib and cardiotoxicity has so far received little attention and thus remains unclear. However, it inhibits HER2 in addition to mutant EGFR, thereby potentially causing cardiotoxicity. The Japanese Society of Internal Medicine 2017-08-01 2017-08-15 /pmc/articles/PMC5596283/ /pubmed/28781309 http://dx.doi.org/10.2169/internalmedicine.8344-16 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Watanabe, Hiromi
Ichihara, Eiki
Kano, Hirohisa
Ninomiya, Kiichiro
Tanimoto, Mitsune
Kiura, Katsuyuki
Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title_full Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title_fullStr Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title_full_unstemmed Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title_short Congestive Heart Failure During Osimertinib Treatment for Epidermal Growth Factor Receptor (EGFR)-mutant Non-small Cell Lung Cancer (NSCLC)
title_sort congestive heart failure during osimertinib treatment for epidermal growth factor receptor (egfr)-mutant non-small cell lung cancer (nsclc)
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5596283/
https://www.ncbi.nlm.nih.gov/pubmed/28781309
http://dx.doi.org/10.2169/internalmedicine.8344-16
work_keys_str_mv AT watanabehiromi congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT ichiharaeiki congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT kanohirohisa congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT ninomiyakiichiro congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT tanimotomitsune congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc
AT kiurakatsuyuki congestiveheartfailureduringosimertinibtreatmentforepidermalgrowthfactorreceptoregfrmutantnonsmallcelllungcancernsclc

Ejemplares similares